Your browser doesn't support javascript.
loading
High-throughput screening of hybridoma supernatants using multiplexed fluorescent cell barcoding on live cells.
Lu, Mei; Chan, Brian M; Schow, Peter W; Chang, Wesley S; King, Chadwick T.
Afiliação
  • Lu M; Therapeutic Discovery, Amgen Inc., South San Francisco, CA 94080, United States. Electronic address: mei@amgen.com.
  • Chan BM; Therapeutic Discovery, Amgen Inc., Burnaby, British Columbia V5A 1V7, Canada.
  • Schow PW; Medical Sciences, Amgen Inc., South San Francisco, CA 94080, United States.
  • Chang WS; Medical Sciences, Amgen Inc., South San Francisco, CA 94080, United States.
  • King CT; Therapeutic Discovery, Amgen Inc., Burnaby, British Columbia V5A 1V7, Canada. Electronic address: chaking@amgen.com.
J Immunol Methods ; 451: 20-27, 2017 12.
Article em En | MEDLINE | ID: mdl-28803843
ABSTRACT
With current available assay formats using either immobilized protein (ELISA, enzyme-linked immunosorbent assay) or immunostaining of fixed cells for primary monoclonal antibody (mAb) screening, researchers often fail to identify and characterize antibodies that recognize the native conformation of cell-surface antigens. Therefore, screening using live cells has become an integral and important step contributing to the successful identification of therapeutic antibody candidates. Thus the need for developing high-throughput screening (HTS) technologies using live cells has become a major priority for therapeutic mAb discovery and development. We have developed a novel technique called Multiplexed Fluorescent Cell Barcoding (MFCB), a flow cytometry-based method based upon the Fluorescent Cell Barcoding (FCB) technique and the Luminex fluorescent bead array system, but is applicable to high-through mAb screens on live cells. Using this technique in our system, we can simultaneously identify or characterize the antibody-antigen binding of up to nine unique fluorescent labeled cell populations in the time that it would normally take to process a single population. This has significantly reduced the amount of time needed for the identification of potential lead candidates. This new technology enables investigators to conduct large-scale primary hybridoma screens using flow cytometry. This in turn has allowed us to screen antibodies more efficiently than before and streamline identification and characterization of lead molecules.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Separação Celular / Ensaios de Triagem em Larga Escala / Citometria de Fluxo / Corantes Fluorescentes / Hibridomas / Anticorpos Monoclonais / Antígenos de Superfície Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Separação Celular / Ensaios de Triagem em Larga Escala / Citometria de Fluxo / Corantes Fluorescentes / Hibridomas / Anticorpos Monoclonais / Antígenos de Superfície Idioma: En Ano de publicação: 2017 Tipo de documento: Article